Abstract B036: Prevalence of non-clear cell renal cell carcinoma based on new WHO classification: Results from a multicenter BUCARE Study

Abstract Background: The reported prevalence of non-clear cell renal cell carcinoma (nccRCC) has varied across studies for years, partially due to evolving WHO classifications and improvements in pathological diagnosis. These changes may have impacted the true prevalence of nccRCC in daily practice. The aim of this large multicenter analysis was to accurately estimate the prevalence of nccRCC in order to understand the relevance of the problem. Methods: A retrospective analysis was conducted at 9 cancer centers across southern, central, and eastern Russia (Chelyabinsk, Ekaterinburg, Kazan, Khabarovsk, Krasnodar, Omsk, Orenburg, Ufa, and Yuzhno-Sakhalinsk). These regions have only one comprehensive cancer center and accumulate all RCC patients. Patients diagnosed with RCC between 2022 and 2023, confirmed histologically with detailed pathological descriptions, were included. Data were collected via an anonymized online registry. The primary outcome was the period prevalence of nccRCC, defined as the proportion of nccRCC cases over a 12-month period. Results: A total of 2,835 adult patients were analyzed, with a mean of 315 patients per region annually. All cases had confirmed RCC subtypes. Of these, 540 patients were diagnosed with nccRCC, yielding a period prevalence of 19.05%. The most common histological subtypes were papillary RCC (7.5%) and chromophobe RCC (6%). Further details on the prevalence of other nccRCC subtypes will be presented at the congress. Conclusions: The study findings confirm previously reported prevalence rates of nccRCC. Notably, any changes in prevalence appear to be associated with shifts within nccRCC subtypes due to the new WHO classification, rather than significant differences in comparison to clear cell RCC. Ongoing analysis will provide further insights into these patterns. Citation Format: Vladislav Petkau, Dmitrii Shemetov, Sufia Safina, Olga Novikova, Alla Goryainova, Evgeny Kopyltsov, Makhabbat Murzalina, Alexander Sultanbaev, Elvira Parsadanova, Grigory Raskin, Ilya Tsimafeyeu. Prevalence of non-clear cell renal cell carcinoma based on new WHO classification: Results from a multicenter BUCARE Study [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Innovations in Kidney Cancer Research: From Molecular Insights to Therapeutic Breakthroughs; 2026 Mar 13-16; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(5_Suppl_2):Abstract nr B036.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-03-13
DOI
https://doi.org/10.1158/1538-7445.kidney26-b036
Primary Topic
Renal cell carcinoma treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract B036: Prevalence of non-clear cell renal cell carcinoma based on new WHO classification: Results from a multicenter BUCARE Study

Sufia Safina, Vladislav Vladimirovich Petkau, Makhabbat Zh. Murzalina, Ilya Tsimafeyeu et al.
Cancer Research
Renal cell carcinoma treatment
article

Abstract B036: Prevalence of non-clear cell renal cell carcinoma based on new WHO classification: Results from a multicenter BUCARE Study

Sufia Safina, Vladislav Vladimirovich Petkau, Makhabbat Zh. Murzalina, Ilya Tsimafeyeu, Evgeny Kopyltsov, Dmitrii Iu. Shemetov, Elvira Parsadanova, Alexander Valerievich Sultanbaev, Olga Novikova, Alla Goryainova, Grigory Raskin
article en

Abstract

Abstract Background: The reported prevalence of non-clear cell renal cell carcinoma (nccRCC) has varied across studies for years, partially due to evolving WHO classifications and improvements in pathological diagnosis. These changes may have impacted the true prevalence of nccRCC in daily practice. The aim of this large multicenter analysis was to accurately estimate the prevalence of nccRCC in order to understand the relevance of the problem. Methods: A retrospective analysis was conducted at 9 cancer centers across southern, central, and eastern Russia (Chelyabinsk, Ekaterinburg, Kazan, Khabarovsk, Krasnodar, Omsk, Orenburg, Ufa, and Yuzhno-Sakhalinsk). These regions have only one comprehensive cancer center and accumulate all RCC patients. Patients diagnosed with RCC between 2022 and 2023, confirmed histologically with detailed pathological descriptions, were included. Data were collected via an anonymized online registry. The primary outcome was the period prevalence of nccRCC, defined as the proportion of nccRCC cases over a 12-month period. Results: A total of 2,835 adult patients were analyzed, with a mean of 315 patients per region annually. All cases had confirmed RCC subtypes. Of these, 540 patients were diagnosed with nccRCC, yielding a period prevalence of 19.05%. The most common histological subtypes were papillary RCC (7.5%) and chromophobe RCC (6%). Further details on the prevalence of other nccRCC subtypes will be presented at the congress. Conclusions: The study findings confirm previously reported prevalence rates of nccRCC. Notably, any changes in prevalence appear to be associated with shifts within nccRCC subtypes due to the new WHO classification, rather than significant differences in comparison to clear cell RCC. Ongoing analysis will provide further insights into these patterns. Citation Format: Vladislav Petkau, Dmitrii Shemetov, Sufia Safina, Olga Novikova, Alla Goryainova, Evgeny Kopyltsov, Makhabbat Murzalina, Alexander Sultanbaev, Elvira Parsadanova, Grigory Raskin, Ilya Tsimafeyeu. Prevalence of non-clear cell renal cell carcinoma based on new WHO classification: Results from a multicenter BUCARE Study [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Innovations in Kidney Cancer Research: From Molecular Insights to Therapeutic Breakthroughs; 2026 Mar 13-16; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(5_Suppl_2):Abstract nr B036.

Cancer ResearchVol. 86(5_Supplement_2)
Kuban State Medical University (RU), Sakhalin State University (RU), Russian Cancer Research Center NN Blokhin (RU), Budgetary Health Care Institution of the Omsk Region "Clinical Oncology Center" (RU), Khabarovsk State University of Economics and Law (RU), Saint-Petersburg Medico-Social Institute (RU), Orenburg Regional Clinical Oncology Center (RU), Republican Oncological Clinical Dispensary (RU), State Healthcare Institution "Regional Clinical Oncological Dispensary" (RU), Chelyabinsk Regional Clinical Oncology Center (RU)
Good health and well-being
Openalex Percentile: Top 23%
Renal cell carcinoma treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.